温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.msd.com/research/business-development-and-licensing
点击访问原文链接

Business development and licensing - MSD

进入原网站 导航首页
Business development and licensing - MSD Skip to content

Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy MSD Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics and compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Supplier help for Ariba Research Research overview Areas of focus Oncology Vaccines Infectious diseases Cardiovascular disease Immunology Neuroscience Ophthalmology Areas of innovation Data science and artificial intelligence Green and sustainable science Our therapeutic modalities Translational medicine Pipeline Business development and licensing Clinical Trials Clinical trials overview Diversity in clinical trials R&D locations How we invent Meet our scientists Publications Safety data sheets (SDS) Product patents Patients Patients overview Play an active role in your health care Fighting counterfeit medicine Media Media overview News releases Company statements Company fact sheet Investors Investors overview Events and presentations Stock information Careers Who we are Learn more Contact us What can we help you find? Search for: Research > Business development and licensing Business development and licensing (BD&L) We’re focused on identifying breakthrough science and collaborating together to make the greatest difference for patients, now and in the future.

Collaborate with us

 

Partner with us

With a robust pipeline and portfolio fueled by both our own discoveries and external innovation, we know that collaborations are critical to advancing bold science. We share your urgency to transform health care for patients and will act decisively when there’s an opportunity to make a meaningful impact on patients’ lives. We leverage our company’s strengths, including our global capabilities from discovery research through commercialization, to work with our partners to bring new and life-changing therapies to patients.

Areas of research | R&D locations | Meet our team | BD&L news I Careers

Accelerating bold science together Searching the world for cutting-edge science regardless of therapeutic area or modality Our areas of focus Cutting-edge science Oncology Vaccines Infectious diseases Cardio-metabolic disorders Immunology Neuroscience Ophthalmology Enabling/platform technologies Pipeline
Animal Health × R&D locations We’re open to collaboration anywhere the science leads us. Our teams are co-located within our research & development sites in Boston, South San Francisco and Rahway— epicenters of scientific innovation.

Search locations × “Our strength is our ability to translate science and develop compounds at scale. We will not be complacent in our pursuit of breakthrough science because patients are waiting.”
Sunil Patel
Senior vice president, head of corporate development and BD&L
Read his bio BD&L stories

What is One Pipeline? How we’re advancing the best internal and external science to progress our pipeline for patients Podcast: Meet the dealmakers  MSD’s business development and licensing team explain how they identify new opportunities to strengthen our robust R&D pipeline   Individualized neoantigen therapies: exploring one medicine for one patient Scientists are researching new ways to help train the immune system to fight cancer

Podcast: Why neuroscience is the ‘final frontier’ Listen as specialists from MSD discuss what they’re most excited about in researching potential treatments for neurologic disorders Previous Next We’re active in dealmaking worldwide

We’re unafraid to make bold investments in external science where we believe we can save and improve lives. See list of select deals.

BD&L news

Recent acquisitions and collaborations With the acquisition of Prometheus Biosciences, we hope to usher in a new era of care for immune disorders based on a precision medicine.

Our acquisition of EyeBio strengthens and diversifies our pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases.

As part of our acquisition of Harpoon Therapeutics, we’re investigating a novel class of T cell engagers designed to harness the power of the body’s immune system and help patients suffering from certain types of cancer and other diseases.

Venture funds The MRL Ventures Fund (MRLV) team invests globally in early-stage, preclinical therapeutics companies focused on delivering innovative therapies to improve patient care. Learn more.

MSD Global Health Innovation Fund (MGHIF) is a growth investor partnering with innovative digital health and data science companies that facilitate and optimize biopharmaceutical operations with the goal of improving patient care. Learn more.

Careers in BD&L Building strong alliances is the most important job we have. Our BD&L organization works with a broad range of partners — from early-stage science to clinical-stage programs — to deliver therapies to waiting patients.

Search jobs

Related links Pipeline We're focused on discovering new solutions for today and the future. Research We believe research is the will to conquer the impossible and that science will lead the way. Suppliers Economic inclusion, small business development and environmental sustainability are core to our procurement practices. Connect with us on social For patients and health care professionals MSD Manuals
Medical information source covering thousands of topics in all fields of medicine Clinical trials
Learn about our clinical trials and find available studies Sustainability Impact Report
Reporting on our commitment to operating responsibly to benefit society MSD for Mothers
An initiative to create a world where no woman has to die giving life About MSD MSD Animal Health
The global animal health business unit of MSD Contact Us
If you have a question or need more information about us, find out who you should contact. Forward-looking statementCookie policyCookie PreferencesPrivacyTerms of useAccessibilitySitemap Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

智能索引记录